Abbott to partner with Pfizer to develop a companion diagnostic check for non-small cell lung cancer Abbott announced today that it has entered into an agreement with Pfizer Inc to develop a molecular diagnostic check intended to screen non-small cell lung tumor tumors for the current presence of gene rearrangements. Pfizer has developed a novel investigational agent that targets cancer-leading to genes implicated in the improvement of several cancers selectively Click here . To be eligible to get Pfizer’s oral therapy, a particular genetic translocation known to be found in NSCLC tumors and a wide variety of other cancers, however, not in normal cells, should be present.
.. Abbott’s Humira gains first-line biologic make use of for psoriasis treatment: Report Decision Resources, among the world’s leading study and advisory companies for pharmaceutical and health care issues, finds that even though Amgen/Stiefel/Pfizer’s Enbrel may be the most popular biologic across all lines of therapy for psoriasis treatment in newly diagnosed individuals, Abbott’s Humira is gaining increasing use as a first-collection biologic at Enbrel’s expense. According to the new statement entitled Treatment Algorithms in Psoriasis, dermatologists’ increasing knowledge of Humira, along using its better efficacy, far more convenient dosing than Enbrel and set up safety profile are the leading elements for Humira’s growing recognition as a first-line biologic choice.